Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.44 USD

197.44
4,182,372

-0.11 (-0.06%)

Updated Aug 26, 2024 04:00 PM ET

Pre-Market: $197.33 -0.11 (-0.06%) 8:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q1 Earnings?

by Zacks Equity Research

AbbVie's (ABBV) Q1 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.

Want To Retire Early? Learn the Intelligent Investing Secret - April 27, 2020

by Zacks Equity Research

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN

by Kinjel Shah

Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $81.47 in the latest trading session, marking a +1.38% move from the prior day.

Sweta Killa headshot

Healthcare ETFs Looks Strong Ahead of Q1 Earnings

by Sweta Killa

The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.

Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter. Stock declines.

AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL

by Zacks Equity Research

AbbVie's (ABBV) regulatory application seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan gets approval from the FDA.

Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.

Sheraz Mian headshot

Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly

by Sheraz Mian

In addition to the Q1 earnings scorecard, today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Oracle (ORCL) and Eli Lilly (LLY).

Powerful Proof Anyone Can Invest for an Early Retirement - April 17, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Why AbbVie (ABBV) Could Beat Earnings Estimates Again

by Zacks Equity Research

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AbbVie (ABBV) Stock Moves -0.51%: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $81.71 in the latest trading session, marking a -0.51% move from the prior day.

J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2020. It lowers its adjusted earnings and sales outlook for 2020 for coronavirus-related uncertainty. Stock up.

AstraZeneca's Koselugo Gets FDA Nod for Rare Genetic Disorder

by Zacks Equity Research

The FDA approves AstraZeneca (AZN) and Merck's kinase inhibitor, Koselugo, for treating pediatric patients with neurofibromatosis type 1 (NF1) having symptomatic, inoperable plexiform neurofibromas.

Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?

by Zacks Equity Research

J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.

Should Value Investors Buy AbbVie (ABBV) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer

by Zacks Equity Research

Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.

Want To Retire Early? Learn the Intelligent Investing Secret - April 09, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, QUALCOMM, PepsiCo and CME Group

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, QUALCOMM, PepsiCo and CME Group

The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products

Top Ranked Income Stocks to Buy for April 8th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 8th.

Kinjel Shah headshot

Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market

by Kinjel Shah

The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $75.27, marking a -0.61% move from the previous day.